|
Trikafta is a real breakthrough for CF patients. What's not mentioned is the cost - about $300 000 per person per year. [1] In 2037 the patent will run out, and the generic price will likely be 90% less. Fortunately, for Americans with good-enough health insurance, it's covered, so ... yay? For those without insurance, or in other countries where $300k is basically unaffordable, well bummer for you, you'll be the last generation to die of it. I get the insane costs, and risks, of developing these things. I get that the profit motive is what drives there to be any research at all in pharma. I get that the price has to be high for everyone, or insurance companies will balk. And yet, even knowing all that, there's a sour taste when we -could- (literally) save lives, but, well, money first ya-know... I don't have an answer to this issue- there are downsides to all proposals I've heard. But this approach seems, well, pretty harsh. [1] https://www.statnews.com/2023/11/03/trikafta-cystic-fibrosis.... |
Unfortunately, that's not guaranteed to bring a price drop. Humira is a good example of that; it recently went generic but much of the savings went to higher rebates to pharmacy benefits managers.
Some reading for anyone curious:
https://www.reuters.com/business/healthcare-pharmaceuticals/...